Reston, VA (March 27, 2026)— New research has been published ahead-of-print by The Journal of Nuclear Medicine ( JNM ). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
A New Way to Track Heart Scarring After Heart Attack
Researchers tested a novel imaging tracer, 99m Tc-(HE)3-(GPO)9, to detect active collagen turnover following myocardial infarction in mice and human tissue. Using SPECT/CT and tissue analysis, they measured tracer uptake, compared it with controls, and linked signals to denatured collagen and fibrosis-related biological changes over time across multiple post-infarction time points.
Sharper Targeting for Ovarian Cancer Imaging
Researchers evaluated folate-based radioconjugates to determine whether 6S-5-MTHF improves selective targeting of folate receptor-α in cancer. Using cell studies, mouse tumor models, imaging, and human tissue analysis, they compared uptake and binding across receptor types, revealing stronger preference of 6S compounds for tumor-associated receptors over those in healthy tissues.
Targeted Radiotherapy Shows Promise for Neuroendocrine Tumors
Researchers tested a DLL3-targeting radiotherapy, 225 Ac-mcp-TDI-Y-010, in mouse models of lung and prostate neuroendocrine cancers. Through biodistribution, dosimetry, and survival studies, they assessed tumor uptake, dosing, and treatment response, finding prolonged survival and manageable toxicity compared with controls across multiple dose levels.
Can Teens Safely Receive Adult-Dose Radiotherapy?
Researchers assessed whether adolescents can safely receive adult dosing of 177 Lu-DOTATATE for rare neuroendocrine tumors. Using pharmacokinetic modeling and dosimetry simulations, they compared drug exposure and radiation to kidneys and bone marrow, finding similar profiles between groups and acceptable predicted safety margins across four treatment cycles.
New Imaging Agent Enters First Human Testing for Neuroendocrine Tumors
Researchers conducted a first-in-human study of 99m Tc-TECANT1, a novel somatostatin receptor antagonist, in patients with neuroendocrine tumors. They evaluated safety, pharmacokinetics, radiation dose, and imaging performance, comparing results with standard PET scans and demonstrating strong lesion detection and improved contrast in metastatic disease.
PET Imaging May Help Predict Outcomes in Recurrent Glioblastoma
Researchers analyzed 18 F-FET PET scans from patients with recurrent glioblastoma to see if tumor imaging could indicate prognosis. They measured metabolic tumor volume and tumor-to-background ratios, finding that higher values were linked to increased risk of death, suggesting these imaging markers could help guide patient selection for future trials.
PSMA PET Scans Outperform PSA in Tracking Advanced Prostate Cancer
In patients with metastatic castration-resistant prostate cancer, researchers compared follow-up PSMA PET/CT imaging with traditional PSA blood tests during 177 Lu-PSMA therapy. They found that changes in volumetric PET metrics, especially total lesion PSMA, closely tracked treatment response and more accurately predicted overall survival than PSA alone.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org .
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
Journal of Nuclear Medicine